Format

Send to

Choose Destination
Curr Opin Chem Biol. 2017 Aug;39:46-53. doi: 10.1016/j.cbpa.2017.05.016. Epub 2017 Jun 9.

Targeted protein knockdown using small molecule degraders.

Author information

1
Arvinas LLC, New Haven, CT 06511, United States.
2
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520, United States; Department of Chemistry, Yale University, New Haven, CT 06520, United States; Department of Pharmacology, Yale University, New Haven, CT 06520, United States. Electronic address: craig.crews@yale.edu.

Abstract

Small molecule probes of biological systems have traditionally been designed to bind to and inhibit the active sites of their protein targets. While this class of pharmacological agents has been broadened by the development of a small number of allosteric and protein-protein interaction (PPI) inhibitors, conventional drug design still excludes 'undruggable' proteins that are neither enzymes nor receptors. Recent years have seen the emergence of new classes of small molecules that can target hitherto undruggable proteins by recruiting the cellular proteostasis machinery to selectively tag them for degradation. These molecules, especially the class known as Proteolysis Targeting Chimera (PROTACs), represent a paradigm shift in chemical genetics, but their most tantalizing potential is as novel therapeutic agents. This review briefly summarizes the preclinical development of small molecule-based protein degraders, and describes the recent improvements in the technology that have positioned PROTACs on the cusp of entering the clinic.

PMID:
28605671
PMCID:
PMC5584562
DOI:
10.1016/j.cbpa.2017.05.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center